Expertise in
8
conditions

Dr. Anna Bruckner

Pediatrics | Dermatology
13123 E 16th Ave, 
Aurora, CO 
Referral may be required
Expertise in
8
conditions
13123 E 16th Ave, 
Aurora, CO 

Overview

Anna Bruckner is a Pediatrics specialist and a Dermatologist practicing medicine in Aurora, Colorado.

Dr. Bruckner is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, Dowling-Meara Epidermolysis Bullosa Simplex, and Dominant Dystrophic Epidermolysis Bullosa.

She is actively involved in clinical research, co-authoring 78 peer reviewed articles and participating in 12 clinical trials.

Specialties

Pediatrics
Dermatology

Licenses

Dermatology in CO

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Denver Health Medical Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Rocky Mountain Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 14 Less Insurance Carriers -

Locations

13123 E 16th Ave, Aurora, CO 80045
Other Locations
13123 E 16th Ave # B-570, Aurora, CO 80045

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa
A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa
Enrollment Status: Active_not_recruiting
Publish Date: March 18, 2026
Intervention Type: Biological
Study Drug: FCX-007 (Dabocemagene Autoficel)
Study Phase: Phase 3
Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label
Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label
Enrollment Status: Terminated
Publish Date: December 01, 2025
Intervention Type: Drug
Study Drug: Sirolimus
Study Phase: Phase 2
Use of Otoscope as a Non-invasive Tool for Diagnosis of Pilomatricoma
Use of Otoscope as a Non-invasive Tool for Diagnosis of Pilomatricoma
Enrollment Status: Completed
Publish Date: December 27, 2024
Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow-up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa
Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow-up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa
Enrollment Status: Completed
Publish Date: July 20, 2023
Intervention Type: Drug
Study Drug: Oleogel-S10
Study Phase: Phase 3
A Phase I/II Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
A Phase I/II Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations
Enrollment Status: Completed
Publish Date: November 17, 2022
Intervention Type: Drug, Other
Study Drug: Sildenafil
Study Phase: Phase 2
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Open-Label Study of PTR-01 in Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
A Phase 2 Open-Label Study of PTR-01 in Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Drug: PTR-01
Study Phase: Phase 2
A First in Human, Double-blind, Randomized, Intra-subject Placebo-controlled, Multiple Dose Study of QR-313 Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With DDEB or RDEB Due to Mutation(s) in Exon 73 of the COL7A1 Gene
A First in Human, Double-blind, Randomized, Intra-subject Placebo-controlled, Multiple Dose Study of QR-313 Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With DDEB or RDEB Due to Mutation(s) in Exon 73 of the COL7A1 Gene
Enrollment Status: Terminated
Publish Date: August 25, 2021
Intervention Type: Drug
Study Drug: QR-313
Study Phase: Phase 1/Phase 2
A Phase 1/2 Randomized, Saline-Controlled, Single-Blind, Multiple Ascending Dose, Dose-Escalation, Multi-Center Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
A Phase 1/2 Randomized, Saline-Controlled, Single-Blind, Multiple Ascending Dose, Dose-Escalation, Multi-Center Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Enrollment Status: Completed
Publish Date: March 09, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

78 Total Publications

Multidisciplinary Management of Epidermolysis Bullosa.
Multidisciplinary Management of Epidermolysis Bullosa.
Journal: Pediatric dermatology
Published: November 17, 2025
Similar Doctors
Expertise in
15
conditions
Dr. Kelly G. Knupp
Pediatrics
Expertise in
15
conditions
Dr. Kelly G. Knupp
Pediatrics

Children's Hospital Colorado

13123 East 16th Avenue, Department Of, 
Aurora, CO 
 (0.1 miles away)
720-777-6895
Experience:
29+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kelly Knupp is a Pediatrics provider practicing medicine in Aurora, Colorado. She has been practicing medicine for over 29 years. Dr. Knupp is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses West Syndrome, Myoclonic Epilepsy, Spasmus Nutans, and Dravet Syndrome. Dr. Knupp is board certified in American Board Of Psychiatry And Neurology and American Board Of Psychiatry And Neurology. Dr. Knupp is currently accepting new patients.

Expertise in
1
conditions
Dr. Amy Tyler
Pediatrics
Expertise in
1
conditions
Dr. Amy Tyler
Pediatrics

Children's Hospital Colorado

13123 E 16th Ave, 
Aurora, CO 
 (0.1 miles away)
720-777-1234
Languages Spoken:
English
See accepted insurances

Amy Tyler is a Pediatrics provider practicing medicine in Aurora, Colorado. Dr. Tyler is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Croup.

Expertise in
13
conditions
Dr. David Norris
Dermatology
Expertise in
13
conditions
Dr. David Norris
Dermatology

University Of Colorado Hospital

1665 Aurora Ct, 
Aurora, CO 
 (0.2 miles away)
720-848-0500
Languages Spoken:
English
See accepted insurances

David Norris is a Dermatologist practicing medicine in Aurora, Colorado. Dr. Norris is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Alopecia Areata, Autosomal Recessive Hypotrichosis, Eosinophilic Fasciitis, and Female Pattern Baldness.

Frequently Asked Questions about Dr. Anna Bruckner

How do I make an appointment with Dr. Anna Bruckner?

You can book an appointment with Dr. Anna Bruckner by calling their office at 720-777-1234. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anna Bruckner a top-rated expert for Epidermolysis Bullosa?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anna Bruckner is classified as an Elite expert for Epidermolysis Bullosa, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anna Bruckner specialize in?

While Dr. Anna Bruckner is a Pediatrics, they have specific expertise in Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, and Dowling-Meara Epidermolysis Bullosa Simplex. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatrics.

Does Dr. Anna Bruckner participate in research or clinical trials?

Yes. Dr. Anna Bruckner has published 78 articles and abstracts on conditions like Epidermolysis Bullosa. You can view a list of Dr. Anna Bruckner's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Anna Bruckner accept my insurance?

Dr. Anna Bruckner accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 720-777-1234 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bruckner's expertise for a condition
ConditionClose
View All 36 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile